Even at the 400mg. dose VX-135 was an inferior drug when compared to sofosbuvir. In my opinion low dosing VX-135 guarantees the VX-135/Simeprevir combo won't be competitive in GT1.
Per Seeking Alpha transcript of today's VRTX CC, it appears VRTX management said during Q&A that the results in the 200mg PK studies of VX-135 compared favorably with the results seen for sofosbuvir at 400mg. Is that not a fair statement?
Market Data 
Markets 
AI
